Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer

Journal of Thoracic Disease

Norihiko Takeda¹  Daiya Takai²  Takahide Nagase³  Haruka Chino³  Jun Matsuda¹  Yasuhiro Yamauchi³  Goh Tanaka³  Yosuke Amano³ 

[1] Department of Cardiovascular Medicine,the University of Tokyo Hospital, Bunkyo-ku, Tokyo, JapanDepartment of Cardiovascular Medicine,the University of Tokyo Hospital, Bunkyo-ku, Tokyo, JapanDepartment of Cardiovascular Medicine,the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan;Department of Clinical Laboratory, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, JapanDepartment of Clinical Laboratory, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, JapanDepartment of Clinical Laboratory, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan;Department of Respiratory Medicine,the University of Tokyo Hospital, Bunkyo-ku, Tokyo, JapanDepartment of Respiratory Medicine,the University of Tokyo Hospital, Bunkyo-ku, Tokyo, JapanDepartment of Respiratory Medicine,the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan

关键词: Non-small cell lung cancer (NSCLC);    bevacizumab;    cardiotoxicity;    chemotherapy;    vascular endothelial growth factor (VEGF);   

DOI  :  10.21037/jtd.2016.08.96

学科分类：呼吸医学

来源: Pioneer Bioscience Publishing Company

【 授权许可】

Unknown